Back to News
Market Impact: 0.18
Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's What You Should Know
Source: zacks.com
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
Analysts' average price target for Progyny implies 25.2% upside. While the article cautions that price-target averages have limited predictive value, broad analyst agreement in raising earnings estimates is presented as a more constructive indicator for the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
PGNY0.42
More News
- How Pepsi fell behind in the cola wars—and then lost KFC
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- Goldman says these top tech stocks have plenty of upside ahead of earnings